文献速递临床试验与 GCP

达格列净治疗射血分数降低的心力衰竭合并阻塞性睡眠呼吸暂停综合征的疗效(DAHOS研究):多中心、前瞻性、随机对照临床试验研究方案

Efficacy of dapagliflozin in the treatment of HFrEF with obstructive sleep apnea syndrome (DAHOS study): study protocol for a multicentric, prospective, randomized controlled clinical trial.
PubMed 文献 · Trials · 2023-05-09

DAHOS研究是一项为期3个月的多中心、前瞻性、随机对照临床试验,纳入左心室射血分数≤40%且呼吸暂停低通气指数≥15的成人患者,随机接受优化心力衰竭治疗联合标准剂量达格列净或仅优化心力衰竭治疗,主要结局为治疗3个月前后呼吸暂停低通气指数的变化。

要点

  • 纳入标准为左心室射血分数≤40%且呼吸暂停低通气指数≥15的成人患者。
  • 干预组接受优化心力衰竭治疗联合标准剂量达格列净,对照组仅接受优化心力衰竭治疗。
  • 主要结局为治疗3个月前后呼吸暂停低通气指数的变化。

核心结论

  • 达格列净是纠正射血分数降低的心力衰竭患者睡眠呼吸障碍的良好候选药物,因其已知作用机制可能对抗该人群中睡眠呼吸障碍的病理生理。

研究设计与样本

  • 多中心、前瞻性、随机对照临床试验,为期3个月。
  • 纳入左心室射血分数≤40%且呼吸暂停低通气指数≥15的成人患者,随机分为优化心力衰竭治疗联合标准剂量达格列净组与仅优化心力衰竭治疗组。
  • 在治疗前及3个月后评估夜间通气多导描记、超声心动图、实验室检查以及生活质量和睡眠呼吸障碍问卷。
  • 试验注册号ChiCTR2100049834,注册日期2021年8月10日。

主要发现

  • 原文未报告研究结果。

关键数值与推荐

  • 主要结局为治疗3个月前后呼吸暂停低通气指数的变化。
  • 纳入标准:左心室射血分数≤40%,呼吸暂停低通气指数≥15。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) is associated with sleep dyspnea (SDB), which plays an adverse role in the pathophysiology of the condition. SDB management in HFrEF, however, remains controversial. HFrEF's medical management has recently made significant progress with the discovery of new therapeutic avenues, namely sodia-glucose cotransporter-2 (SGLT-2) inhibitors, and better treatment of co-morbidities. Dapagliflozin, one of the SGLT-2 inhibitors, is a good candidate for correcting SDB of HFrEF patients because their known mechanisms of action are likely to counteract the pathophysiology of SDB in HFrEF. METHODS/DESIGN: The trial is a 3-month, multicentric, prospective, randomized controlled clinical study. Patients (i.e., adults with left ventricular ejection fraction ≤ 40%, Apnoea-Hypopnoea Index ≥ 15) will be randomized to receive optimized heart failure therapy plus a standard dose of dapagliflozin, while the control group will receive only optimized heart failure therapy. Patients will be evaluated before and after 3 months (nocturnal ventilatory polygraphy, echocardiography, laboratory testing, and quality-of-life and SDB questionnaires). The primary outcome is the change in the Apnoea-Hypopnoea Index, before and after 3 months of treatment. TRIAL REGISTRATION: www.chictr.org.cn , ChiCTR2100049834. Registered 10 August 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Xie L, Song S, Li S, et al. Efficacy of dapagliflozin in the treatment of HFrEF with obstructive sleep apnea syndrome (DAHOS study): study protocol for a multicentric, prospective, randomized controlled clinical trial. Trials. 2023. PMID: 37158922. doi:10.1186/s13063-023-07332-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。